THỜI GIAN SỐNG THÊM Ở BỆNH NHÂN U LYMPHO TẾ BÀO ÁO ĐIỀU TRỊ TẠI VIỆN HUYẾT HỌC – TRUYỀN MÁU TRUNG ƯƠNG GIAI ĐOẠN 2021–2024

Abstract

Objective: This study aimed to analyze overall survival and associated prognostic factors in patients with mantle cell lymphoma (MCL) treated at the National Institute of Hematology and Blood Transfusion (NIHBT) during the period 2021–2024. Methods: A descriptive case series study, combining retrospective and prospective data collection, was conducted on 57 newly diagnosed MCL patients, of whom 46 met the criteria for analysis. Variables included clinical and laboratory characteristics, TP53/IGHV mutations, MIPI/MIPI-c scores, Ki-67, LDH levels, and chemotherapy regimens. Overall survival (OS) and event-free survival (EFS) were analyzed using the Kaplan–Meier method via SPSS version 20.0. Results: The mean age of patients was 61.6 ± 9.4 years, with 75.4% being male. The estimated median OS was 23.7 months, with 12- and 24-month OS rates of 76% and 65.9%, respectively. The median EFS was 21.6 months, with 12- and 24-month EFS rates of 71.5% and 63.4%. Patients with Ki-67 <30% and LDH <460 UI/L showed better survival outcomes. Those in the low-intermediate MIPI-c risk group had superior OS and EFS. TP53 mutation was associated with poor prognosis, while IGHV gene rearrangements were linked to durable treatment responses. Conclusion: Chemotherapy shows favorable treatment outcomes in MCL patients; however, survival prognosis remains influenced by biological factors such as MIPI-c, Ki-67, LDH, and genetic mutations.